PMID- 34459679
OWN - NLM
STAT- MEDLINE
DCOM- 20220208
LR  - 20220501
IS  - 1532-4206 (Electronic)
IS  - 0743-5800 (Linking)
VI  - 47
IP  - 1
DP  - 2022 Feb
TI  - Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor 
      Agonists: Analysis of Real-world Databases.
PG  - 18-25
LID - 10.1080/07435800.2021.1955255 [doi]
AB  - BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP1Ra) are commonly used 
      in type 2 diabetes mellitus (T2DM). However, differential risk of various cancers 
      among GLP1Ra recipients is unknown. METHODS: We inquired an aggregated electronic 
      health record database, Explorys, and compared the adjusted odds ratio (aOR) of 
      cancers between GLP1Ra and metformin users. Findings were validated in the FDA 
      Adverse Event Reporting System (FDA FAERS). RESULTS: From 1/2005 to 6/2019, we 
      identified 619 340 and 64 230 patients in the metformin and GLP1Ra group, 
      respectively. Within 5 years of starting antidiabetic medications, GLP1Ra was 
      associated with significantly lower incident risk of prostate (aOR 0.81, p 
      = .03), lung (aOR 0.81, p = .05), and colon cancer (aOR 0.85, p = .03), while the 
      risk of thyroid cancer was significantly higher (aOR 1.65, p < .01). Similar 
      findings were seen in the FDA FAERS database, where GLP1Ra was associated with 
      lower risk of prostate (aOR 0.72, p = .08), lung (aOR 0.52, p < .01), colon 
      cancer (aOR 0.82, p = .31), and higher risk of thyroid cancer (aOR 4.33, p 
      < .01). In addition, with longer duration of GLP1Ra use, the risk of prostate, 
      lung, and colon cancer further decreased, suggesting an exposure 
      duration-response relationship. CONCLUSIONS: GLP1Ra is associated with lower 
      risks of prostate, lung, and colon cancer, but higher risk of thyroid cancer.
FAU - Wang, Jiasheng
AU  - Wang J
AD  - Department of Internal Medicine, MetroHealth Medical Center, Case Western Reserve 
      University, Cleveland, OH, USA.
FAU - Kim, Chang H
AU  - Kim CH
AD  - Division of Hospital Medicine, MetroHealth Medical Center, Case Western Reserve 
      University, Cleveland, OH, USA.
LA  - eng
PT  - Journal Article
DEP - 20210830
PL  - England
TA  - Endocr Res
JT  - Endocrine research
JID - 8408548
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/chemically induced/drug therapy/epidemiology
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Male
MH  - *Metformin
MH  - *Neoplasms/chemically induced/epidemiology
OTO - NOTNLM
OT  - GLP1 receptor agonist
OT  - colon cancer
OT  - lung cancer
OT  - prostate cancer
OT  - thyroid cancer
EDAT- 2021/08/31 06:00
MHDA- 2022/02/09 06:00
CRDT- 2021/08/30 12:15
PHST- 2021/08/31 06:00 [pubmed]
PHST- 2022/02/09 06:00 [medline]
PHST- 2021/08/30 12:15 [entrez]
AID - 10.1080/07435800.2021.1955255 [doi]
PST - ppublish
SO  - Endocr Res. 2022 Feb;47(1):18-25. doi: 10.1080/07435800.2021.1955255. Epub 2021 
      Aug 30.